Clinical trials: Radiation-Induced Neoplasms
HPV-Related Squamous Cell Carcinoma, HNSCC
Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer
Carboplatin, nab-paclitaxel, and nivolumab combination will be administered for three cycles of three weeks duration each. TORS or RT/CRT will be performed after induction chemotherapy (i.e. day 64 of therapy).
- Trial name
- OPTIMA-II (NCT03107182)
- Testing
- nab-paclitaxel, Carboplatin, Nivolumab
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- University of Chicago
Ganglioneuroblastoma, Localized Resectable Neuroblastoma
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
This pilot clinical trial studies induction therapy followed by iobenguane I 131 and chemotherapy in treating patients with newly diagnosed high-risk neuroblastoma undergoing stem cell transplant, radiation therapy, and…
- Conditions
- Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma
- Trial name
- NCT01175356
- Testing
- 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Busulfan
- Where
- 25 sites in United States
- Volunteers
- 99 people
- Sponsor
- Children's Oncology Group
Head and Neck Cancer
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00089297
- Testing
- Cetuximab, Carboplatin, Paclitaxel
- Volunteers
- 74 people
- Sponsor
- Eastern Cooperative Oncology Group
Head and Neck Cancer
Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer
This research is being performed to treat patient for head and neck cancer patients who have not received prior chemotherapy.
- Trial name
- NCT03894891
- Testing
- Nivolumab, Cisplatin, Docetaxel
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Dana-Farber Cancer Institute
Esophageal Cancer, Gastroesophageal Cancer
Oxaliplatin-Based Chemotherapy and Chemoradiotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Carcinoma
The goal of this clinical research study is to learn if a combination of the investigational drug oxaliplatin with 5-Fluorouracil (5-FU) (given at the same time as radiation therapy) is as effective as a combination of these two…
- Trial name
- NCT00525915
- Testing
- 5-Fluorouracil, Oxaliplatin, Radiation Therapy
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- M.D. Anderson Cancer Center
Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer
This randomized phase III trial studies pelvic radiation therapy to see how well it works compared with vaginal implant radiation therapy, paclitaxel, and carboplatin in treating patients with high-risk stage I or stage II…
- Conditions
- Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Fatigue, Neurotoxicity Syndrome
- Trial name
- NCT00807768
- Testing
- 3-Dimensional Conformal Radiation Therapy, Carboplatin, Intensity-Modulated Radiation Therapy
- Where
- 540 sites in United States, South Korea
- Volunteers
- 601 people
- Sponsor
- Gynecologic Oncology Group
Breast Carcinoma, Radiation-Induced Dermatitis
Topical Keratin in Treating Radiation Dermatitis in Patients With Breast Cancer
This randomized pilot clinical trial studies how well topical keratin works in treating radiation dermatitis in patients with breast cancer.
- Trial name
- NCT03374995
- Testing
- Best Practice, Quality-of-Life Assessment, Topical Keratin
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Wake Forest University Health Sciences
Head and Neck Cancer
Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer
The purpose of this study is to explore the activity of ZD1839 added to concurrent chemoradiotherapy and as adjuvant monotherapy in patients with locally advanced head and neck cancer.
- Trial name
- NCT01185171
- Testing
- ZD 1839 500mg
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Chicago
Extrahepatic Bile Duct Cancer, Nausea
Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer
This pilot clinical trial is studying how well aprepitant works in preventing nausea and vomiting in patients undergoing chemotherapy and radiation therapy for pancreatic cancer.
- Conditions
- Extrahepatic Bile Duct Cancer, Nausea, Vomiting, Stage II Pancreatic Cancer
- Trial name
- NCT01534637
- Testing
- aprepitant, gemcitabine hydrochloride, capecitabine
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Wake Forest University Health Sciences
Head and Neck Cancer
Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some find tumor cells and kill them or carry tumor-killing substances to them.
- Trial name
- NCT00301028
- Testing
- Cetuximab, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Diseases, Carcinoma, Non-Small-Cell Lung
Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)
Open-label, non-randomized, phase II multi-centre controlled clinical trial. 51 non-resectable stage IIIA-IIIB non-small cell lung cancer patients will be enrolled in this trial to evaluate the efficacy of the treatment…
- Conditions
- Lung Diseases, Carcinoma, Non-Small-Cell Lung, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
- Trial name
- APOLO (NCT04776447)
- Testing
- Carboplatin, Placlitaxel, Atezolizumab
- Where
- 22 sites in Spain
- Volunteers
- 38 people
- Sponsor
- Fundación GECP
Head and Neck Cancer, Xerostomia
Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer
RATIONALE: Acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) and pilocarpine may help to relieve chronic xerostomia (dry mouth).
- Trial name
- NCT00656513
- Testing
- Pilocarpine, ALTENS
- Where
- 20 sites in United States, Canada
- Volunteers
- 196 people
- Sponsor
- Radiation Therapy Oncology Group
Lung Cancer
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Trial name
- NCT00553462
- Testing
- carboplatin, erlotinib hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation
- Where
- 99 sites in United States
- Volunteers
- 78 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Squamous Cell Carcinoma of the Head and Neck
Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer
This phase two trial will determine the tumor response rate at the primary site and at involved regional nodes to two cycles of an IC regimen of weekly Abraxane and cetuximab given in combination with cisplatin and 5-FU in…
- Trial name
- NCT00736944
- Testing
- Abraxane, Cetuximab, Cisplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Washington University School of Medicine
Breast Cancer
An Integrated Consent Model Study to Compare Two Standard of Care Schedules for Monitoring Cardiac Function in Patients Receiving Trastuzumab for Early Stage Breast Cancer
Several large adjuvant trastuzumab trials have demonstrated improved overall survival in participants with early stage breast cancer, with a 33% decrease in risk of death.
- Trial name
- OTT 15-05 (NCT02696707)
- Testing
- LVEF 3 month, LVEF 4 month
- Where
- 4 sites in Canada
- Volunteers
- 200 people
- Sponsor
- Ottawa Hospital Research Institute
Chemotherapeutic Agent Toxicity, Cognitive/Functional Effects
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and help kill them or carry cancer-killing substances to them.
- Conditions
- Chemotherapeutic Agent Toxicity, Cognitive/Functional Effects, Lymphoma, Neurotoxicity
- Trial name
- NCT01399372
- Testing
- Rituximab, Cytarabine, Methotrexate
- Where
- 45 sites in United States, Israel
- Volunteers
- 91 people
- Sponsor
- Radiation Therapy Oncology Group
Squamous Cell Carcinoma of the Head and Neck, Human Papilloma Virus
Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study
In this research study, the investigators are studying whether a reduced dose of radiation when given with standard doses of chemotherapy can reduce side effects without compromising control of the cancer.
- Trial name
- NCT01221753
- Testing
- docetaxel, cisplatin, 5-FU
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Dana-Farber Cancer Institute
Chemo-radiation Induced Nausea and Vomiting
Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide
The purpose of this phase 2 study is to assess the efficacy and patient satisfaction of oral rolapitant plus ondansetron vs. oral ondansetron monotherapy in malignant glioma (MG) patients receiving standard of care radiation (RT)…
- Trial name
- NCT02991456
- Testing
- Rolapitant, Ondansetron
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Duke University
Metastatic Melanoma, Brain Metastases
Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery
This is a study to test the efficacy of using standard immune therapy for melanoma prior to stereotactic radiosurgery (ipilimumab induction), as compared to stereotactic radiosurgery followed by immune therapy.
- Trial name
- NCT02097732
- Testing
- Ipilimumab, Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Michigan Rogel Cancer Center
Head and Neck Squamous Cell Carcinoma
Transdermal Buprenorphine for the Treatment of Radiation-Induced Mucositis Pain in Head and Neck Cancer Patients
This is a single-arm prospective clinical trial to determine the safety and feasibility of using transdermal buprenorphine in alleviation of radiation induced mucositis pain in head and neck cancer patients.
- Trial name
- NCT04752384
- Testing
- Buprenorphine, Tramadol, Oral Mucositis (OM) Pain App
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Medical College of Wisconsin